Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement.

19 Sep 2018

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New Zealand.

For further details see the attachment below.

STX_Exclusive Licence Agreement

Back to news